|
Volume 21, Issue 3 (May 2019) 21, 253–259; DOI:10.4103/aja.aja_32_18
Beta-adrenergic signaling on neuroendocrine differentiation, angiogenesis, and metastasis in prostate cancer progression
Yicheng Zhao1,2,3, Wenliang Li1,2,3
1 Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
2 Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
3 Division of Oncology, Department of Internal Medicine, and Memorial Herman Cancer Center, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Correspondence: Dr. W Li (wenliang.li@uth.tmc.edu)
29-May-2018
| Abstract |
|
Prostate cancer is a complex, heterogeneous disease that mainly affects the older male population with a high-mortality rate. The mechanisms underlying prostate cancer progression are still incompletely understood. Beta-adrenergic signaling has been shown to regulate multiple cellular processes as a mediator of chronic stress. Recently, beta-adrenergic signaling has been reported to affect the development of aggressive prostate cancer by regulating neuroendocrine differentiation, angiogenesis, and metastasis. Here, we briefly summarize and discuss recent advances in these areas and their implications in prostate cancer therapeutics. We aim to provide a better understanding of the contribution of beta-adrenergic signaling to the progression of aggressive prostate cancer.
Keywords: angiogenesis; beta-adrenergic signaling pathway; metastasis; neuroendocrine differentiation; prostate cancer
Full Text |
PDF |
|
| |
| Browse: 3230 |
|
